Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00096798|
Recruitment Status : Completed
First Posted : November 16, 2004
Last Update Posted : January 17, 2008
|Condition or disease||Intervention/treatment||Phase|
|Depressive Disorder Depression||Drug: Ethyl-eicosapentanoic acid (ethyl-EPA)||Phase 3|
Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. This study will determine whether ethyl-EPA, an omega-3 fatty acid, can be used safely and effectively to treat major depression.
Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks. Each week, participants will be asked to complete questionnaires which will be used to assess the severity of their depression.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder|
|Study Start Date :||September 2001|
|Actual Primary Completion Date :||August 2007|
|Actual Study Completion Date :||August 2007|
- Alleviation of depressive symptoms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00096798
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||David Mischoulon, MD, PhD||Massachusetts General Hospital|